GSK Wants UK to Open Up Health Records to Boost Drug Development
This article is for subscribers only.
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life science rankings.
The British drugmaker wants the government to invest in more effectively linking clinical, genomic and primary care datasets together and to make them available to researchers and companies.